Publications by authors named "I Riviere"
MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical trial included 17 patients and determined that MCARH109 is safe at a maximum tolerated dose of 150 × 10 CAR T cells. In this updated analysis, no new serious adverse events were reported at a median follow-up of 37 months.
View Article and Find Full Text PDFArticle Synopsis
- * The trial included 28 patients and showed promising results with an overall response rate of 82%, and a complete response rate of 71%, especially in a subgroup treated with a low dosage of CAR T cells (25×10).
- * With a median follow-up of 24 months, the therapy demonstrated a 1-year event-free survival rate of 61%, while serious side effects were relatively low, indicating the potential for this approach in treating
Article Synopsis
- Researchers are working on a new type of therapy called CAR therapy to fight a blood cancer called acute myeloid leukemia (AML).
- This new strategy aims to attack cancer cells while making sure it doesn’t harm the body’s healthy blood cells.
- The therapy combines two special receptors to more effectively target the cancer cells, and it has shown promise in experiments, potentially offering a treatment that doesn’t need further help from the body.